Ceciel Rooker joined IFFGD in July 2017, bringing with her to the organization over a decade of experience in the field of functional gastrointestinal and motility disorders (FGIMDs). She has worked extensively with patients and their families as well as health professionals to improve FGIMD education and patient care.

Ceciel has taken part in advocacy efforts in the US, meeting with policy makers on Capitol Hill and providing testimony to the US Food and Drug Administration (FDA) on behalf of the millions of Americans affected by a FGIMD. She has traveled internationally to encourage patient and professional education and advance research into these conditions.

To learn more about Ms. Rooker, read her story here.

Ceciel headshot resized

Professional Societies and Appointments

 

  • Ms. Rooker provides the patient voice by serving on many professional societies. Her roles include:
  • Council Member (Ad-Hoc), NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Advisory Council; 2020 - Present
  • Working Group Member, NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Strategic Plan Committee; 2019-Present
  • Digestive Disease National Coalition (DDNC)
  1. Nominating Committee; 2020 - Present
  2. Member-at-large, DDNC Executive Committee; 2018 – Present
  3. Member; 2017- Present
  • Member, American Gastroenterological Association; 2019-Present
  • Member, Patient Reported Outcomes (PRO) Consortium, IBS Working Group, Critical Path Institute; 2018-Present
  • Member, American Society of Association Executives; 2018-Present
  • Member, American Neurogastroenterology and Motility Society; 2017–Present
  • Advisor, Fecal Incontinence in Primary Care Consortium; 2017–Present

Publications:

  • Mediaplanet, Rooker C. Five Signs It’s More Than Acid Reflux or Heartburn. Future of Personal Health, Digestive Health and Wellness. https://www.futureofpersonalhealth.com/digestive-wellness/5-signs-its-more-than-acid-reflux-or-heartburn/
  • Drossman DA, Morris CB, Davis CE, Weinland SR, Aderoju AO, Kulkani-Kelapure RR, Hu YB, Houpe ME, Zimmerman Y, Rooker C, Bangdiwala SI. Narcotic Bowel Syndrome: Characterization of 30 patients and preliminary results after detoxification. Gastroenterol, 140(5), Suppl 1: S-465, 2011.
  • Drossman DA, Morris CB, Wrennall CED, Weinland SR, Aderoju AO, Kulkarni-Kelapure RR, Hu YJ, Dalton C, Bouma MH, Zimmerman J, Rooker C, Leserman J, Bangdiwala SI. Diagnosis, Characterization, and 3 Month Outcome of 39 Patients with Narcotic Bowel Syndrome. AM J GASTRO, Advance Online Publication June 19, 2012. http://www.nature.com/ajg/journal/vaop/ncurrent/full/ajg2012142a.html
About IFFGD
Leadership
Nancy J. Norton, IFFGD Founder
Ceciel T. Rooker, IFFGD President
Advisory Board
Officers and Board of Directors
Editorial Board Members
Our Mission
Awareness Activities & Accomplishments
Public Education & Awareness
Professional Education & Awareness
Year in Review
-2017
-2015
-2014
-2012/2013
Advocacy Activities
Legislative Successes
FGIMD Act (Functional Gastrointestinal and Motility Disorders Research Enhancement Act)
Congressional Testimony
FISCAL YEAR 2020
FISCAL YEAR 2019
FISCAL YEAR 2013
FISCAL YEAR 2012
FISCAL YEAR 2010
FISCAL YEAR 2009
FISCAL YEAR 2008
FISCAL YEAR 2007
FISCAL YEAR 2006
FISCAL YEAR 2005
FISCAL YEAR 2004
FISCAL YEAR 2003
FISCAL YEAR 2016
FDA and Other Testimony
Written Comments to FDA December 30, 2019
Written Comments to FDA October 15, 2019
Written Comments to SSA September 23, 2019
Written comments to FDA April 30, 2019
Written Comments to SSA February 15, 2019
Written Comments to HHS February 5, 2019
Written Comments to DoD December 13, 2018
Written Comments to FDA October 18, 2018
Written Comments to FDA October 17, 2018
Written Presentation to FDA September 12, 2017
Written Comments to FDA June 29, 2015
Oral Comments to FDA May 11, 2015
Comments to FDA July 16th, 2014
Written Comments to Noridian October 24, 2013
Testimony to FDA October 25, 2012
Testimony to FDA September 12, 2012
Testimony to FDA December 13, 2011
Testimony to FDA December 2, 2010
Testimony to FDA April 23, 2002
Comments to FDA November 9, 2000
Testimony to FDA June 27, 2000
Testimony to FDA June 26, 2000
Capitol Hill Advocacy Day
National Institutes of Health (NIH)
CDC
FDA
Research
IFFGD Research Awards
IFFGD Symposium reports
2013 Professional Symposium
10th Symposium Report
10th Symposium Audio Recordings
More from the 10th Symposium on FGIDs
2011 Professional Symposium
9th Symposium Report
2009 Professional Symposium
2007 Professional Symposium
7th Symposium Report
2005 Professional Symposium
6th Symposium Report
2003 Professional Symposium
5th Symposium Report
2002 Conference - Advancing the Treatment of Incontinence
Funding
Corporate Support
Our Research Funding Needs
IFFGD Standards for Collaboration
Industry Council
Code of Ethics
Contact Us
Media Contact
Donation

Join the Conversation

join conversation

Keep up-to-date on the latest news, stories, tips, research highlights, and more!

Sign up for eNewsletter

Connect through Facebook

Follow us on Twitter